Vistagen Q3 FY2026 net loss $18.9M; PALISADE-4 topline expected H1 2026

Vistagen Therapeutics, Inc.

2026-Q3 EPS reported -$1.46 revenue$804,000

Net loss $18.9M for quarter ended Dec 31, 2025, vs $14.1M a year ago; R&D expense $14.2M, G&A $5.6M.
Cash and equivalents $61.8M as of Dec 31, 2025; company targeting disciplined capital allocation.
PALISADE-4 Phase 3 trial of fasedienol for social anxiety ongoing; topline results from randomized portion expected H1 2026.
Previous PALISADE-3 Phase 3 missed primary endpoint in Dec 2025; safety data favorable.
Appointed Nick Tressler as CFO in Dec 2025; refisolone IND submission for hot flashes planned H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.